EMYRIA LIMITED (ASX: EMD)
Health care · News and insights
Price unavailable
Latest EMD announcements
Announcement Insights
Emyria’s FY26 Revenue Rises 191% As Clinic Network Expands
Emyria reported FY26 revenue of approximately $4 million, up 191% from FY25, as its treatment network grew to five clinics and 18 beds. Its September-quarter update showed revenue of approximately $1 million, about double the same quarter a year earlier, and the opening of its first Sydney clinic; the company also reported initial Department of Veterans’ Affairs patient approvals and late-stage discussions with a pharmaceutical sponsor, with no agreement finalised.
Updated 12 Nov 2026, 05:53 PM Sydney time
Sources
2026 Annual General Meeting PresentationResults of Annual General MeetingNotification of cessation of securities - EMDSeptember 2026 Quarterly Investor Webinar PresentationSeptember 2026 Quarterly Investor Update Webinar InvitationSeptember 2026 Quarterly Activities Report and Appendix 4CComments
2026-11-12 · Health care
EMD: $0.038 +2.70% · MC: $31M
Emyria shareholders passed all resolutions at the annual meeting, including approval of a company name change and a 10% placement facility. The accompanying presentation highlights FY26 revenue of $4 million, up 191% from FY25, alongside expansion to five clinics and 18 treatment beds.
Updated 2026-11-12 17:39
Sources
2026 Annual General Meeting PresentationResults of Annual General MeetingComments
2026-11-10 · Health care
EMD: $0.036 +0.00% · MC: $31M
Emyria reported that more than 21 million options expired without being exercised or converted. The company’s ordinary shares remain at over 806 million on issue.
Updated 2026-11-10 16:43
Sources
Notification of cessation of securities - EMDComments
2026-11-02 · Health care
EMD: $0.040 +2.56% · MC: $31M
Emyria’s webinar presentation reports FY26 revenue of approximately $4 million, up 191%, and says its network now spans four states, with 18 treatment beds and more than 160 patients treated. The figures follow its September-quarter update, which reported record quarterly revenue of approximately $1 million and the opening of its first Sydney clinic.
Updated 2026-11-02 13:29
Sources
September 2026 Quarterly Investor Webinar PresentationComments
2026-10-30 · Health care
EMD: $0.039 +0.00% · MC: $31M
Emyria will hold a webinar on 2 November, where its executive chairman and chief operating officer are scheduled to present a quarterly investor update. The invitation follows the company’s September-quarter report, which disclosed record quarterly revenue and the launch of its Sydney clinic.
Updated 2026-10-30 08:59
Sources
September 2026 Quarterly Investor Update Webinar InvitationComments
2026-10-29 · Health care
EMD: $0.039 -4.88% · MC: $31M
Emyria reported record quarterly revenue of approximately $1 million, up from approximately $0.5 million in the same quarter last year, and opened its first Sydney clinic, expanding its network to four states with capacity for up to 90 dosing sessions a week. It received initial Department of Veterans’ Affairs patient approvals, with more than 40 referrals in its pipeline, and appointed former US Veterans Affairs Secretary Dr David Shulkin as a strategic adviser to support US opportunities. The company also said it is in late-stage discussions with an international pharmaceutical sponsor, but no agreement has been finalised.
Updated 2026-10-29 09:54
Sources
September 2026 Quarterly Activities Report and Appendix 4CComments
Comments